Laurus Labs' share price surged 8% to an all-time high of ₹901, driven by strong Q1 FY26 earnings. Analysts raised target ...

In Q1FY26, the CDMO segment registered a revenue of Rs 522 crore, marking a 103% year-on-year (YoY) rise from Rs 257 crore in ...

Laurus Labs rallies to 52-week high after strong Q1, but analysts remain cautious with downside risk of up to 33 per cent.

The company has a CDMO pipeline of 90+ human health projects, wherein 15 products are commercialised, targeting APIs and ...

Laurus Bio 与 Liberation Labs 等国外企业在合成生物领域的快速扩张和技术布局，可能会抢占全球市场份额，加剧行业竞争，对中国生物制造企业的市场 ...

Given the higher-margin profile of CDMO and operating leverage as new manufacturing assets ramp, brokerage firms expect ...

Shares of Laurus Labs Ltd rose 6% on July 28 to hit a fresh all-time high on the company's strong Q1 results and allotment of nearly 532 acres by Andhra Pradesh government for establishment of Laurus ...

Laurus Labs shares are trading at 58 times its financial year 2027 price-to-earnings and Kotak Institutional Equities ...

A CNBC-TV18 poll is expecting Laurus Labs to report a revenue growth of 27% from last year to ₹1,514.2 crore, while its ...

Laurus Lab ’s net profit increased manifold to ₹163 crore in the first quarter of the current fiscal ended June 30, 2025 ...

Laurus Labs to invest ₹5,630 crore in Andhra Pradesh for Pharma Zone, creating jobs and securing land for expansion.